Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug combo takes on tough cancers

NCT ID NCT05407675

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose. The study is now complete, but results on effectiveness are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BMS-986408 (an experimental drug) combined with nivolumab (Opdivo) and/or ipilimumab (Yervoy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that haven't responded to other therapies.
What could go wrong
This is an early-phase trial focused on safety and dosing, not yet on effectiveness. The combination may cause severe side effects, and it's unknown if it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

68 people

The number who actually took part.

Started

Aug 2022

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy of any histology measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Participants who have received, been refractory to, ineligible for, or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant * Participants with melanoma should have documentation of mutation status for B-type Raf proto-oncogene (BRAF) and neuroblastoma ras viral oncogene homolog (NRAS) * Participants must have experienced radiographically documented progressive disease on or after the most recent therapy Exclusion Criteria: * An active, known or suspected autoimmune disease * Conditions requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment * Current or recent gastrointestinal disease or gastrointestinal surgery that could impact the absorption of study drug * Untreated central nervous system (CNS) metastases or leptomeningeal metastasis Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors

Contacts and locations

Locations

  • Local Institution - 0001

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 0003

    Houston, Texas, 77030, United States

  • Local Institution - 0005

    Ottawa, Ontario, K1H 8L6, Canada

  • Local Institution - 0006

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0007

    Edmonton, Alberta, T6G 1Z2, Canada

  • Local Institution - 0010

    Boston, Massachusetts, 02215, United States

  • Local Institution - 0011

    Hamilton, Ontario, L8V5C2, Canada

  • Local Institution - 0012

    Basel, 4031, Switzerland

  • Local Institution - 0014

    Villejuif, Paris, 94800, France

  • Local Institution - 0015

    Bordeaux, Aquitaine, 33076, France

  • Local Institution - 0018

    Marseille, 13385, France

  • Local Institution - 0019

    Toulouse, 31059, France

  • Local Institution - 0020

    Geneva, 1205, Switzerland

  • Local Institution - 0021

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

  • Local Institution - 0022

    Madrid, Madrid, 28040, Spain

  • Local Institution - 0023

    Madrid, Madrid, 28050, Spain

  • Local Institution - 0024

    Málaga, Andalusia, 29010, Spain

  • Local Institution - 0025

    Madrid, Madrid, Comunidad de, 28009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.